Beacon Therapeutics
Beacon Therapeutics
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-06-25 | NCT07174726 | |
| A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-07 | NCT04850118 | |
| A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Enrolling by invitation | Phase 2 | 2024-10-30 | NCT06275620 | |
| A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2024-08-12 | NCT06333249 | |
| Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations | Eye Diseases, Hereditary, eye disorder, retinal degeneration, retinal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2024-05-20 | NCT03316560 |